GlassScriptPhysician profile
Julie Ann Estep
NPI 1366890626
$6,223.64
in general payments reported to CMS, 2019-2025
22 companies · $1,647 in 2025
The $1,647 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,053 · 2022: $815 · 2023: $1,097 · 2024: $1,612 · 2025: $1,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,257 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,256.59 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,582.19 | 2021-2025 | |
| Ucb, INC. | $946.20 | 2021-2025 | Cimzia, Bimzelx |
| Amgen INC. | $734.42 | 2021-2025 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $710.52 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $659.93 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $515.49 | 2021-2025 | Saphnelo |
| Pfizer INC. | $239.23 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.97 | 2021-2024 | Cyltezo, Ofev |
| E.R. Squibb & Sons, L.L.C. | $167.44 | 2021-2025 | Orencia |
| Lilly USA, LLC | $111.62 | 2023-2024 | Taltz |
| Glaxosmithkline, LLC. | $63.31 | 2021-2025 | Benlysta |
| Fresenius Kabi USA, LLC | $52.41 | 2023 | Idacio |
| Sobi, INC | $42.50 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $35.53 | 2022-2024 | Acthar |
| Aurinia Pharma U.S., INC. | $33.47 | 2024 | Lupkynis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $30.26 | 2024 | Purified Cortrophin Gel |
| United Therapeutics Corporation | $26.89 | 2024 | Tyvaso |
| Ultragenyx Pharmaceutical INC. | $24.18 | 2021 | |
| Sandoz INC. | $24.02 | 2023 | Hyrimoz |
| Ibsa Pharma INC. | $20.50 | 2021 | |
| Genzyme Corporation | $18.19 | 2023 | |
| Genentech USA, INC. | $15.37 | 2024 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Estep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.